Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745–60.

Article  CAS  PubMed  Google Scholar 

Leong DP, Caron F, Hillis C, Duan A, Healey JS, Fraser G, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128:138–40.

Article  CAS  PubMed  Google Scholar 

Alexandre J, Boismoreau L, Morice PM, Sassier M, Da-Silva A, Plane AF, et al. Atrial Fibrillation Incidence Associated With Exposure to Anticancer Drugs Used as Monotherapy in Clinical Trials. JACC CardioOncol. 2023;5:216–26.

Article  PubMed  PubMed Central  Google Scholar 

Baptiste F, Cautela J, Ancedy Y, Resseguier N, Aurran T, Farnault L, et al. High incidence of atrial fibrillation in patients treated with ibrutinib. Open Heart. 2019;6:e001049.

Article  PubMed  PubMed Central  Google Scholar 

Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134:1919–28.

Article  PubMed  PubMed Central  Google Scholar 

Wu H, Wang W, Liu F, Weisberg EL, Tian B, Chen Y, et al. Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol. 2014;9:1086–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xiao L, Salem JE, Clauss S, Hanley A, Bapat A, Hulsmans M, et al. Ibrutinib-Mediated Atrial Fibrillation Due to Inhibition of CSK. Circulation. 2020;142:2443–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buck B, Chum AP, Patel M, Carter R, Nawaz H, Yildiz V, et al. Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity. JAMA Oncol. 2023;9:552–5.

Article  PubMed  PubMed Central  Google Scholar 

EMA. European Medicines Agency. 2018. Imbruvica. Disponible sur: https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica

Quartermaine C, Ghazi SM, Yasin A, Awan FT, Fradley M, Wiczer T, et al. Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2023;5:570–90.

Article  PubMed  PubMed Central  Google Scholar 

Thompson PA, Lévy V, Tam CS, Al Nawakil C, Goudot FX, Quinquenel A, et al. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol. 2016;175:462–6.

Article  CAS  PubMed  Google Scholar 

Singh A, El Hangouche N, McGee K, Gong FF, Lentz R, Feinglass J, et al. Utilizing left atrial strain to identify patients at risk for atrial fibrillation on ibrutinib. Echocardiography. 2021;38:81–8.

Article  PubMed  Google Scholar 

Brown JR, Moslehi J, O’ Brien S, Ghia P, Hillmen P, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102:1796–805.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alexandre J, Salem JE, Moslehi J, Sassier M, Ropert C, Cautela J, et al. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother. 2021;7:312–20.

Article  PubMed  Google Scholar 

Faillie JL. Case-non case studies: Principles, methods, bias and interpretation. Therapie. 2018;73:247–55.

Sarosiek S, Gustine JN, Flynn CA, Leventoff C, Little M, White T, et al. Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib. Br J Haematol. 2023;201:897–904.

Article  CAS  PubMed  Google Scholar 

Chen H, Cohen P, Chen S. How Big is a Big Odds Ratio? Interpreting the Magnitudes of Odds Ratios in Epidemiological Studies. Commun Stat Simul Comput. 2010;39:860–4.

Article  Google Scholar 

Jiang L, Li L, Ruan Y, Zuo S, Wu X, Zhao Q, et al. Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium. Heart Rhythm. 2019;16:1374–82.

Article  PubMed  Google Scholar 

Isaza N, Bolen MA, Griffin BP, Popović ZB. Functional Changes in Acute Eosinophilic Myocarditis Due to Chemotherapy With Ibrutinib. CASE. 2019;3:71–6.

Article  PubMed  PubMed Central  Google Scholar 

Kaptein A, De Bruin G, Emmelot-van Hoek M, Van De Kar B, De Jong A, Gulrajani M, et al. Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies. Blood. 2018;132:1871.

Article  Google Scholar 

Patel V, Balakrishnan K, Bibikova E, Ayres M, Keating MJ, Wierda WG, et al. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clin Cancer Res. 2017;23:3734–43.

Article  CAS  PubMed  Google Scholar 

Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, et al. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 2022;107:1335–46.

Article  CAS  PubMed  Google Scholar 

Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014;114:1453–68.

Article  CAS  PubMed  Google Scholar 

Tuomi JM, Xenocostas A, Jones DL. Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib. Can J Cardiol. 2018;34:337–41.

Article  PubMed  Google Scholar 

Tuomi JM, Bohne LJ, Dorey TW, Jansen HJ, Liu Y, Jones DL, et al. Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis. J Am Heart Assoc. 2021;10:e022369.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022;43:4229–361.

Article  PubMed  Google Scholar 

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373–498.

Article  PubMed  Google Scholar 

Font J, Milliez P, Ouazar AB, Klok FA, Alexandre J. Atrial fibrillation, cancer and anticancer drugs. Arch Cardiovasc Dis. 2023;116:219–26.

Article  PubMed  Google Scholar 

Halcox JPJ, Wareham K, Cardew A, Gilmore M, Barry JP, Phillips C, et al. Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study. Circulation. 2017;136:1784–94.

Article  PubMed  Google Scholar 

Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. 2024. Disponible sur: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50.

Williams AM, Baran AM, Casulo C, Reagan P, Friedberg JW, Helber M, et al. Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience. Clin Lymphoma Myeloma Leuk. 2019;19:41–7.

Article  PubMed  Google Scholar 

Narezkina A, Lu X, Emond B, Côté-Sergent A, Hilts A, Liu S, et al. Real-World Persistence and Time to Next Treatment with Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke. Blood. 2021;138:4112.

Article  Google Scholar 

Prada-Ramallal G, Takkouche B, Figueiras A. Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review. BMC Med Res Methodol. 2019;19:53.

Article  PubMed  PubMed Central